Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ironwood Pharmaceuti (IRWD)

Ironwood Pharmaceuti (IRWD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 732,056
  • Shares Outstanding, K 162,679
  • Annual Sales, $ 351,410 K
  • Annual Income, $ 880 K
  • EBIT $ 123 M
  • EBITDA $ 125 M
  • 60-Month Beta 0.18
  • Price/Sales 2.31
  • Price/Cash Flow 90.98
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 100.75% (+11.24%)
  • Historical Volatility 89.51%
  • IV Percentile 6%
  • IV Rank 7.33%
  • IV High 784.43% on 03/14/25
  • IV Low 46.65% on 03/26/25
  • Expected Move (DTE 31) 0.99 (21.53%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 132
  • Volume Avg (30-Day) 1,208
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 15,796
  • Open Int (30-Day) 13,076
  • Expected Range 3.59 to 5.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.02
  • Number of Estimates 2
  • High Estimate 0.03
  • Low Estimate 0.01
  • Prior Year 0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.08 +48.70%
on 12/22/25
5.78 -20.76%
on 01/02/26
+1.45 (+46.33%)
since 12/19/25
3-Month
1.47 +211.46%
on 10/30/25
5.78 -20.76%
on 01/02/26
+3.04 (+197.40%)
since 10/20/25
52-Week
0.53 +768.91%
on 05/16/25
5.78 -20.76%
on 01/02/26
+0.92 (+25.14%)
since 01/17/25

Most Recent Stories

More News
Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating

Ironwood Pharmaceuticals rose 30% after a strategic price cut on Linzess unlocked higher revenue guidance and surprised Wall Street analysts.

IRWD : 4.58 (+1.78%)
ABBV : 214.04 (-0.14%)
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

- Expects full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million - ...

IRWD : 4.58 (+1.78%)
Ironwood: Q3 Earnings Snapshot

Ironwood: Q3 Earnings Snapshot

IRWD : 4.58 (+1.78%)
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

– LINZESS ® (linaclotide) U.S. net sales of $315 million in Q3 2025, an increase of 40% year-over-year; EUTRx demand growth increased 12% year-over-year – ...

IRWD : 4.58 (+1.78%)
Ironwood Pharma Board Member Resigns for New Role

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Ironwood...

IRWD : 4.58 (+1.78%)
Ironwood: Q2 Earnings Snapshot

Ironwood: Q2 Earnings Snapshot

IRWD : 4.58 (+1.78%)
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance

– LINZESS ® (Iinaclotide) U.S. net sales of $248 million in Q2 2025; EUTRx demand growth of 10% year-over-year – ...

IRWD : 4.58 (+1.78%)
Ironwood: Q1 Earnings Snapshot

Ironwood: Q1 Earnings Snapshot

IRWD : 4.58 (+1.78%)
Ironwood Shares Tank on Regulatory Update for Apraglutide

Shares of Ironwood Pharmaceuticals IRWD plunged 31.5% yesterday after it announced regulatory updates on the next-generation GLP-2 analog, apraglutide, which is being developed for treating short bowel...

KRYS : 274.81 (-3.59%)
IRWD : 4.58 (+1.78%)
JAZZ : 167.88 (-0.90%)
ADMA : 17.59 (+1.62%)
Ironwood: Q4 Earnings Snapshot

Ironwood: Q4 Earnings Snapshot

IRWD : 4.58 (+1.78%)

Business Summary

Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic...

See More

Key Turning Points

3rd Resistance Point 5.19
2nd Resistance Point 4.91
1st Resistance Point 4.74
Last Price 4.58
1st Support Level 4.29
2nd Support Level 4.01
3rd Support Level 3.85

See More

52-Week High 5.78
Last Price 4.58
Fibonacci 61.8% 3.77
Fibonacci 50% 3.15
Fibonacci 38.2% 2.53
52-Week Low 0.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar